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Molecular detection techniques continue to increase in util-
ity in clinical microbiology laboratories. The implementation
of in vitro nucleic acid amplification techniques, led by real-
time PCR, in diagnostic laboratories has transformed viral
detection and select bacterial detection. Although not likely to
completely replace culture techniques in the near future, mo-
lecular applications in the diagnosis of infectious diseases have
become commonplace in academic medical centers and ter-
tiary-care facilities and are becoming more tangible in com-
munity-based settings as more FDA-cleared products are avail-
able. The further advancement of molecular infectious disease
diagnostics is dependent on the ability of multiplexing technol-
ogies, or the ability to detect and identify more than one
pathogen simultaneously from the same specimen, to be im-
plemented in clinical microbiology laboratories with ease and
accuracy. One approach to multiplex detection and character-
ization is microarray analysis.
Simply defined, a microarray is a collection of microscopic
features (most commonly DNA) which can be probed with
target molecules to produce either quantitative (gene expres-
sion) or qualitative (diagnostic) data. Although other types of
microarrays exist, such as protein microarrays (122, 125), this
review will focus on DNA microarrays. The initial production
of arrays in the research arena included radiolabeled macroar-
rays such as Southern blots and dot blots (91, 177). Scientific
ingenuity in research laboratories in the 1990s led to the de-
velopment of modern two-dimensional hybridization microar-
rays (167, 172). Largely due to advances in fabrication, robot-
ics, and bioinformatics, microarray technology has continued
to improve in terms of efficiency, discriminatory power, repro-
ducibility, sensitivity, and specificity (135). In addition, mi-
croarray platforms have expanded to include three-dimen-
sional arrays or suspension bead arrays. These improvements
have allowed the transition of microarrays from strictly re-
search settings to clinical diagnostic applications. The number
of articles on microarrays and articles describing their use in
microbiology and infectious diseases has rapidly increased over
the past 9 years (Fig. 1). Although many of these articles can
still be attributed to clinical microbiology or infectious disease
“research,” research in the diagnostic realm has led to the
optimization of the diagnostic potential of microarrays and has
led to the development of commercially available qualitative
detection platforms. Thus, we have now entered a new era in
molecular diagnostics where the use of microarray technology
in clinical microbiology is a reality.
BASIC CONCEPTS OF MICROARRAYS
Microarrays can be distinguished based upon characteristics
such as the nature of the probe, the solid-surface support used,
and the specific method used for probe addressing and/or
target detection (135). Below, we review the methodologies of
printed and in situ-synthesized microarrays, high-density bead
arrays, and electronic and suspension bead microarrays. In all
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of these approaches, the probe refers to the DNA sequence
bound to the solid-surface support in the microarray, whereas
the target is the “unknown” sequence of interest. In general
terms, probes are synthesized and immobilized as discrete fea-
tures, or spots. Each feature contains millions of identical
probes. The target is fluorescently labeled and then hybridized
to the probe microarray. A successful hybridization event be-
tween the labeled target and the immobilized probe will result
in an increase of fluorescence intensity over a background
level, which can be measured using a fluorescent scanner (135).
The fluorescence data can then be analyzed by a variety of
methods. Experimental details including probe length and syn-
thesis, number of possible features (i.e., density of the microar-
ray), and the solid surface used vary depending on the type of
microarray employed and are discussed below and summarized
in Table 1. The goals of the manuscript are to review the
concepts behind each of these microarray technologies, high-
lighting their benefits and disadvantages, as well as provide a
detailed review of the applications of these techniques in clin-
ical microbiology.
Printed Microarrays
Printed arrays were the first microarrays utilized in research
laboratories and are so called because of the “printing” or
spotting of the probes onto the microarray surface, which is
most commonly a glass microscope slide. Glass slides are an
attractive medium for microarrays because they are economi-
cal; are stable throughout high temperatures and stringent
washes; are nonporous, allowing for efficient kinetics during
hybridization; and have minimal background fluorescence
(25). The probe spots, or features, can be applied by either
noncontact or contact printing. A noncontact printer uses the
same technology as computer printers (i.e., bubble jet or ink-
jet) to expel small droplets of probe solution onto the glass
slide. In contact printing, each print pin directly applies the
probe solution onto the microarray surface. The result in both
cases is the application of a few nanoliters of probe solution
per spot to create an array of 100- to 150-m features. During
the printing process it is imperative to control for cross-con-
tamination and printing consistency to preserve the integrity of
the microarray and subsequent hybridization data. Due to the
relatively large size of the features, printed microarrays are of
lower density (10,000 to 30,000 features) than in situ-synthe-
sized microarrays and high-density bead arrays (discussed be-
low) but offer considerably more features than either elec-
tronic microarrays or suspension bead arrays. The general
workflow for the processing of printed microarrays is depicted
in Fig. 2.
Printed arrays can be further classified based upon the na-
ture of the probes: double-stranded DNA (dsDNA) or oligo-
nucleotide microarrays. For dsDNA microarrays, the probes
consist of amplification products (amplicons) obtained by PCR
using primers designed from a known genomic sequence, shot-
gun library clones, or cDNA (74, 167, 194). The double-
stranded amplicons are denatured, either in print buffer or
after immobilization, which allows the probes to be available
for hybridization. Amplicons can be attached to the glass slide
surface by the electrostatic interaction of the negative charge
of the phosphate backbone of the DNA with a positively
charged coating of the slide surface (51) or by UV-cross-linked
covalent bonds between the thymidine bases in the DNA and
amine groups on treated slides (25). Typically, each 200- to
800-bp dsDNA probe represents a different gene. Ideally, PCR
amplicons for microarrays should have high specificity and
yield but no contamination, including nonspecific amplification
and contaminants that affect attachment to the microarray
surface or that autofluoresce (19). Unfortunately, dsDNA
probes generally have a high sensitivity but suffer in specificity.
For example, in a report by Hager, 21 to 34% of probes did not
match the intended target and/or were contaminated (72). The
ultimate assessment of probe specificity is sequencing of the
products. However, due to financial constraints, most labora-
tories test the purity and quantity of the amplified product by
agarose gel electrophoresis. The specificity of hybridization
FIG. 1. Microarray publications. The number of primary manuscripts published using microarray technology (bars) and the number of
microarray publications that have infectious disease and/or microbiology applications (line) are depicted.
























































































































































































































































































































































































































VOL. 22, 2009 MICROARRAYS IN CLINICAL MICROBIOLOGY 613
data can be improved by incorporating redundancy by the
inclusion of multiple gene segments among the probes. Al-
though decreased specificity can be beneficial when analyzing a
genomic sequence rich in natural polymorphisms, it is disad-
vantageous when trying to discriminate among highly similar
target sequences and unacceptable for clinical diagnostic ap-
plications (105).
The spotted probes of oligonucleotide microarrays consist of
short, chemically synthesized sequences. In contrast to the
relatively large size of dsDNA probes discussed above, the
length of probes typically used in printed oligonucleotide mi-
croarrays ranges from 25 to 80 bp but may be as long as 150 bp
for gene expression microarrays (30). The use of shorter probe
lengths allows fewer errors to be introduced during probe
synthesis and facilitates the interrogation of small genomic
regions, including polymorphisms. While the decreased probe
length may adversely affect sensitivity compared to dsDNA
probes, specificity is often greater when short, specific genomic
regions are interrogated. Longer probes have higher melting
temperatures and greater mismatch tolerance, leading to de-
creased specificity. Generally, the strength of the hybridization
signal and the sensitivity increase with an increasing length of
the probe. The addition of spacers coupled to very short oligo-
nucleotides or the application of a higher concentration of
probe during printing can improve the hybridization signal
strength (30). Ramdas et al. reported an eightfold increase in
sensitivity with 70-mer oligonucleotides relative to the sensi-
tivity of 30-mer probes, especially for low-expression genes
(159). Since, as with dsDNA probes, very long oligonucleotide
probes may decrease specificity due to random hybridization to
nontarget sequences, it is critical to cautiously determine the
optimal probe length for each microarray design. Although
easier to manufacture than dsDNA probes, oligonucleotide
probes require careful design so that all probes have compa-
rable melting temperatures (within 5°C) and lack palindromic
sequences. Preferably, each probe should be tested experimen-
tally to guarantee nonbiased hybridization data, although this
may not always be financially possible (30). Oligonucleotide
probes are attached to glass slides by covalent linkage because,
due to their small size, a significant quantity of probes would be
lost during wash steps after noncovalent electrostatic immobi-
lization and cross-linking. The probes are coupled to the mi-
croarray surface via modified 5 or 3 ends (most commonly a
5 amino group) on coated slides that provide aldehyde or
epoxy functional groups.
Compared to the in situ-synthesized microarrays discussed
below, printed microarrays are relatively simple and inexpen-
sive. However, the initial setup of microarray facilities is costly
and requires dedicated space in which environmental variables
such as dust, humidity, and temperature are well controlled.
Dedicated microarray core facilities are available at many uni-
versities, making these challenges minimal for individual in-
vestigators. A major advantage of printed microarrays is flex-
ibility. The ability to quickly adjust spotted probes based upon
updated annotations or the discovery of new, emerging patho-
gens or resistance mechanisms makes printed microarrays at-
tractive for use in clinical microbiology. However, the imple-
mentation of a printed microarray in a clinical diagnostic
laboratory is complicated by the arduous and expensive tasks
of monitoring production reproducibility, performing clinical
validation studies, and continuously assessing the quality of
downstream data. A major drawback in the manufacturing of
printed dsDNA microarrays is the enormous scale of amplicon
production and the associated difficulties of quality control,
information management, efficiency, and accuracy. Likewise,
the design of oligonucleotide probes is labor-intensive, and
errors introduced from probe synthesis are a problem. Al-
though printed microarrays are conducive to “homebrew” or
user-defined testing, their use in diagnostic microbiology re-
mains limited to specific research applications. Printed dsDNA
FIG. 2. Workflow summary of printed microarrays. Probes are PCR amplified (or oligonucleotides are synthesized) and subsequently spotted
onto a glass slide. In this example, two samples to be compared undergo RNA extraction, cDNA production, and differential fluorescent labeling.
Hybridization of labeled target nucleic acids to the probe array allows fluorescent scanning to provide data for analysis. (Adapted from reference
51 [Fig. 1A, © Springer-Verlag 2006] with kind permission from Springer Science and Business Media.)
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microarrays are also crucial to the study of organisms that have
not been fully sequenced. The lack of commercially available
printed microarrays for use in clinical infectious disease diag-
nostics makes it unlikely that printed microarrays will soon
transition to clinical microbiology laboratories. There are,
however, commercially available whole-genome microarrays
for select organisms that are useful for research endeavors.
In Situ-Synthesized Oligonucleotide Microarrays
In situ-synthesized arrays are extremely-high-density mi-
croarrays that use oligonucleotide probes, of which GeneChips
(Affymetrix, Santa Clara, CA) are the most widely known.
Unlike the printed oligonucleotide arrays described above, the
oligonucleotide probes are synthesized directly on the surface
of the microarray, which is typically a 1.2-cm2 quartz wafer.
Because in situ-synthesized probes are typically short (20 to 25
bp), multiple probes per target are included to improve sensi-
tivity, specificity, and statistical accuracy. Classically, 11 probes
are used per 600 bases being examined (38). The use of probe
sets further increases the specificity. A probe set includes one
perfect-match probe and one mismatch probe that contains a
1-bp difference in the middle position of the probe (i.e., posi-
tion 13 of a 25-bp probe). Each member of the probe set is
located in a separate feature, which allows the mismatch probe
to act as a negative control to identify possible nonspecific
cross-hybridization events. Recent advances in GeneChips in-
clude the use of longer probes, the design of arrays that inter-
rogate across entire genes or exons, and the implementation of
multiple independent and nonoverlapping perfect-match
probes in lieu of classic probe sets.
Affymetrix GeneChips typically have 106 features per mi-
croarray depending on the interfeature distance (38, 59). Gene-
Chip oligonucleotide probes are synthesized using semicon-
ductor-based photochemical synthesis. On the quartz surface
are synthesis linkers modified with light-sensitive protecting
groups (59). Thus, the microarray surface is chemically pro-
tected from a nucleotide addition until deprotected by light.
When the array surface is exposed to UV light, reactive nucle-
otides modified with a photolabile protecting group can be
added to growing oligonucleotide chains. To target specific
nucleotides to exact probe sites, photolithographic masks are
used. Each photolithographic mask has a defined pattern of
windows, which acts as a filter to either transmit or block UV
light from specific features on the chemically protected mi-
croarray surface. Areas of the microarray surface in which UV
light has been blocked will remain protected from the addition
of nucleotides, whereas areas exposed to light will be depro-
tected, and specific nucleotides can be added. The pattern of
windows in each mask directs the order of nucleotide addition.
In situ probe synthesis is therefore accomplished through the
cycling of masking, light exposure, and the addition of either A,
C, T, or G bases to the growing oligonucleotide (Fig. 3)
(38, 51).
Other high-density oligonucleotide microarrays include
those manufactured by Roche NimbleGen (Madison, WI) and
Agilent Technologies (Palo Alto, CA). Both platforms use
longer oligonucleotide probes (60 to 100 bp), but NimbleGen
uses maskless photo-mediated synthesis, and Agilent employs
inkjet technology for the in situ manufacturing of the probes.
While experiments performed with GeneChips are limited to
one label, the NimbleGen and Agilent platforms allow multi-
color hybridizations. As mentioned above for printed microar-
rays, the use of longer oligonucleotides increases sensitivity.
The Roche NimbleGen approach to in situ synthesis is similar
to that of the GeneChips described above, but photolitho-
graphic masks are replaced by “virtual” or digital masks in
Roche NimbleGen’s maskless array synthesizer technology.
Maskless array synthesizer technology uses an array of pro-
grammable micromirrors to create digital masks that reflect
the desired pattern of UV light to deprotect the features where
the next nucleotide will be coupled (Fig. 4). Each NimbleGen
microarray can contain 106 features and can be purchased in
the following formats per slide: 1  2.1 million features, 3 
720,000 features, 1  385,000 features, 4  72,000 features,
and 12  135,000 features. In contrast to the quartz wafers
used for the above-described technologies, Agilent microarrays
use glass slides and inkjet printing, which eliminates the need
for either lithographic or digital masks (Fig. 5). The in situ
synthesis of 60-mer oligonucleotides is achieved using five-
“ink” (4 bases plus catalyst) printing of nucleotide precursors
combined with coupling and deprotection steps (83). Agilent
microarrays are available in the following formats: 1  244,000
features, 2  105,000 features, 4  44,000 features, and 8 
15,000 features.
Due to the complex nature of chemical synthesis and the
expense involved in production, synthesized microarrays are
dependent on commercial manufacturing and are therefore
not conducive to user-defined development. There is a growing
number of microbial genome microarrays available commer-
cially for gene expression studies. Also, several resequencing
microarrays have been developed by TessArae (Potomac Falls,
VA) on the Affymetrix GeneChip platform to simultaneously
detect and differentiate large numbers of microbial pathogens
(115, 116). Currently, a synthesized oligonucleotide array ap-
propriate for use in a diagnostic microbiology laboratory would
need to be ordered as a custom microarray. The expense of a
custom Affymetrix microarray and the inherent inflexibility of
its custom mask make the use of an Affymetrix-synthesized
array impractical for the clinical laboratory. In contrast, other
in situ-synthesized platforms (Nimblegen and Agilent) can be
easily customized with unique oligonucleotide sequence con-
tent. Furthermore, a Web-based tool provided by Agilent
(eArray) allows users to custom design microarrays with no
minimum manufacturing batch size, making Agilent microar-
rays a primary choice for homebrew and pilot applications.
Although it is relatively expensive to obtain a custom oligonu-
cleotide array, many universities already have one or more of
these platforms on campus for hybridization and analysis,
which may offset the upfront costs. The major advantages to
these systems are the reproducibility of the manufacturing
process and the standardization of reagents, instrumentation,
and data analysis, all of which are critical for methodologies to
transition to the clinical laboratory (38). Further advantages
that make this approach attractive for clinical diagnostics in-
clude controls, such as reference probes for intensity normal-
ization; internal standards of known concentrations; and
probes arranged in a checkerboard pattern that are homolo-
gous to an internal control included in the hybridization mix.
Whether printed or synthesized, oligonucleotide microar-
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rays generally allow much cleaner downstream hybridization
data than do amplicon-based microarrays. With oligonucleo-
tide arrays, the ability to standardize probe concentrations and
hybridization temperatures while avoiding or controlling for
significant nonspecific hybridization has resulted in consider-
able improvements in the accuracy and reproducibility of mi-
croarray data (105). Although in situ-synthesized oligonucleo-
tide microarrays are very robust systems and have significant
control measures included, there are currently none with direct
diagnostic infectious disease applications that are commer-
cially available.
High-Density Bead Arrays
Similar to the printed and in situ-hybridized microarrays
discussed above, BeadArrays (Illumina, San Diego, CA) pro-
vide a patterned substrate for the high-density detection of
target nucleic acids. However, instead of glass slides or silicon
wafers as direct substrates, BeadArrays rely on 3-m silica
beads that randomly self-assemble onto one of two available
substrates: the Sentrix Array Matrix (SAM) or the Sentrix
BeadChip (Fig. 6) (52, 146). The SAM contains 96 1.4-mm
fiber-optic bundles. Each bundle is an individual array consist-
ing of 50,000 5-m light-conducting fibers, each of which is
chemically etched to create a microwell for a single bead (52).
In the universal BeadArray, up to 1,536 bead types (each with
a unique capture sequence) assemble onto each fiber bundle,
resulting in 30 beads of each type in the array (146). Each
SAM allows the analysis of 96 independent samples. The Bead-
Chip can be used to assay 1 to 16 samples at a time on a silicon
slide that has been processed by microelectromechanical sys-
tems technology to provide microwells for individual beads
(53). BeadChips are more appropriate for very-high-density
applications such as whole-genome genotyping, which requires
105 to 106 features for determining genome-wide single nucle-
otide polymorphisms (SNP) (Infinium assay; Illumina) (70).
Unlike the known locations of printed and in situ-hybridized
microarray features, the beads in BeadArrays randomly assort
to their final location on the array. Thus, the bead location
must be mapped, which is accomplished by a decoding process
(71). This “decoding” process is in contrast to the use of in-
ternal dyes for “encoding” the Luminex microspheres dis-
cussed in “Suspension Bead Arrays” below. Each bead has
700,000 copies of a unique capture oligonucleotide co-
valently attached to it, which serves as the bead’s identifier
(107). In the universal arrays, the capture sequences specifi-
cally avoid homology with human and mouse nucleic acid se-
quences and are referred to as IllumiCodes. The mapping of
FIG. 3. Affymetrix GeneChip oligonucleotide microarray. (Top) Photolithography. UV light is passed through a lithographic mask that acts as
a filter to either transmit or block the light from the chemically protected microarray surface (wafer). The sequential application of specific
lithographic masks determines the order of sequence synthesis on the wafer surface. (Bottom) Chemical synthesis cycle. UV light removes the
protecting groups (squares) from the array surface, allowing the addition of a single protected nucleotide as it is washed over the microarray.
Sequential rounds of light deprotection, changes in the filtering patterns of the masks, and single nucleotide additions form microarray features
with specific 25-bp probes. (Adapted from reference 38 with permission of the publisher [copyright Elsevier Inc. 2006].)
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the Illumina beads is accomplished by a series of hybridization
and rinse steps, allowing fluorescently labeled complementary
oligonucleotides to bind to their specific bead sequence (Illu-
miCode) and thus track the location of the bead type (52). An
additional advantage to the decoding process is the quality
control provided for each feature of the microarray (53).
The SAM can be processed using a standard microtiter
plate, which makes it amenable to standard automation and
high-throughput processing. The distance between individual
arrays on the 16-sample BeadChip is identical to that of a
standard multichannel pipettor, thereby facilitating ease of
use. BeadArrays can support up to 105 to 106 features and have
built-in redundancy. This redundancy is a crucial experimental
control for intermicroarray comparative data since each man-
ufactured microarray will not be identical. An additional ad-
vantage to the uniqueness of each microarray is that altering
the bead pattern provides a means to identify spatial bias.
Although the analysis tools available for BeadArray-specific
data analysis, background correction, and spatial artifact rec-
ognition have been lagging behind those provided by other
microarray manufacturers, independent researchers have be-
gun to fill the gaps (20, 47, 49, 50, 182, 217). BeadArrays have
been successfully applied to DNA methylation studies (12, 13),
gene expression profiling (14, 54, 107), and SNP genotyping,
including the International HapMap Project (www.hapmap
.org) (23, 53, 70).
Electronic Microarrays
The printed and in situ-synthesized microarrays and Bead-
Arrays described above rely on passive transport for the hy-
bridization of nucleic acids. In contrast, electronic microarrays
utilize active hybridization via electric fields to control nucleic
acid transport. Microelectronic cartridges (NanoChip 400;
Nanogen, San Diego, CA) use complementary metal oxide
semiconductor technology for the electronic addressing of nu-
cleic acids (175). Each NanoChip cartridge has 12 connectors
that control 400 individual test sites. Negatively charged nu-
cleic acids are transported to specific sites, or features, when a
positive current is applied to one or more test sites on the
FIG. 4. Roche NimbleGen oligonucleotide microarray. Maskless array synthesizer technology is depicted, which utilizes a digital micromirror
device (DMD) to create virtual masks. The DMD forms the pattern of UV light needed to direct the specific nucleic acid addition during
photo-mediated synthesis. UV light removes the photolabile protecting group (circles) from the microarray surface, allowing the addition of a
single protected nucleotide to the growing oligonucleotide chain. The cycling of DMD filtering, light deprotection, and nucleotide addition creates
oligonucleotide features 60 to 100 bp in length on the NimbleGen microarray. (Courtesy of Roche NimbleGen [copyright Roche NimbleGen,
Inc.].)
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microarray. The surface of the microarray contains streptavi-
din, which allows for the formation of streptavidin-biotin
bonds once electronically addressed biotinylated probes reach
their targeted location. The positive current is then removed
from the active features, and new test sites can be activated by
the targeted application of a positive current. Once the probes
have been hybridized at discrete features, the microarray is
ready for the application of fluorescently labeled target DNA.
Typically, target DNA passively hybridizes with the immobi-
lized probes on the microarray but can also be concentrated
electronically (Fig. 7). Although addressing the capture probe
down first is the most commonly used format, amplicon-down
and sandwich assays have also been utilized. Regardless of the
addressing format used, if hybridization occurs between the
probe and the target DNA, fluorescent reporters will be
present at the positive test, which will be detected when the
electronic microarray is scanned and analyzed.
Electronic microarrays offer several advantages. For exam-
ple, multiplex detection can be accomplished at an individual
test site since multiple probes, each with a distinct fluorophore,
can be sequentially addressed to the same feature. The flexi-
bility of this platform allows nucleic acids from a single sample
to be hybridized to multiple (but not necessarily all) test sites
for the detection of multiple targets, or nucleic acids from
multiple samples can be analyzed on the same microarray
cartridge, minimizing waste. Furthermore, the NanoChip is a
universal blank chip, and the content of the microarray is
specified directly by the user, which allows more flexibility in
assay design and decreases costs associated with microarray
manufacturing. Although the density of electronic microarrays
is currently limited to 400 spots, this is sufficient for the ma-
jority of diagnostic microbiology applications. In 2007, Nano-
gen announced the termination of its microarray business.
Nonetheless, this technology demonstrates the evolution of
microarray technology to a platform that is more practical for
diagnostic applications.
Suspension Bead Arrays
In contrast to the two-dimensional, or planar, arrays dis-
cussed above, suspension bead arrays are essentially three-
dimensional arrays based on the use of microscopic polysty-
rene spheres (microspheres or beads) as the solid support and
flow cytometry for bead and target detection. Furthermore,
they are distinct from the high-density Illumina BeadArrays
discussed above, in which the beads are immobilized on fiber-
optic strands or silicon slides. Suspension-bead-based assays
were initially described in 1977 and focused on the detection of
antigens and antibodies (78). Multiplexing was first achieved
by using different-sized microsphere sets for the simultaneous
detection of multiple antibodies (130, 169). Currently, more-
robust multiplexing is accomplished using different micro-
sphere sets based on color. Red (658-nm emission) and infra-
red (712-nm emission) fluorochromes are used at various
FIG. 5. Agilent oligonucleotide microarray. (A) Noncontact inkjet printing technology delivers a small and accurate volume (picoliters) of
nucleotides to the first layer on the microarray surface. (B) Repeated rounds of base-by-base printing extend the length of specific oligonucleotide
probes. (C) Close-up of growing oligonucleotide chain with a base being added. (D) The final product is a 60-mer in situ-synthesized probe as a
feature on a microarray containing thousands of specifically synthesized probes. (Images courtesy of Agilent Technologies.)
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concentrations to fill 5.6-m microspheres. Each bead of the
100-microsphere set has a distinct red-to-infrared ratio, and
therefore, each bead has a unique spectral address (Fig. 8A).
Microspheres with a specific spectral address coupled to a
specific probe are equivalent to a feature in a planar microar-
ray. Once multiple individual microspheres have been coupled
to separate specific probes, a mixture of microspheres (in the-
ory, up to 100) can be used to interrogate extracted and am-
plified nucleic acids (Fig. 8B). The subsequent detection of a
fluorescent reporter that indicates probe-target DNA hybrid-
ization is accomplished using a bench-top flow cytometer. A
single-file microsphere suspension passes by two lasers. A
635-nm laser excites the red and infrared fluorochromes im-
pregnated in the microspheres, which allows the classification
of the bead and therefore the identity of the probe-target being
analyzed. A 532-nm laser excites reporter fluorochromes such
as R-phycoerythrin and Alexa 532 to quantify any hybridization
that occurs on the microsphere (Fig. 8C).
Several chemistries have been developed for nucleic acid
detection by suspension bead arrays, including direct DNA
hybridization, competitive DNA hybridization, and solution-
based chemistries with microsphere capture (48). In direct
DNA hybridization, PCR amplicons hybridize directly to probe
capture sequences immobilized on the microspheres (Fig. 8B)
(8, 179). Generally, a biotinylated primer is used during am-
plification, which allows streptavidin–R-phycoerythrin to bind
and label hybridized microspheres. Competitive DNA hybrid-
ization utilizes unlabeled PCR amplicons and biotinylated
competitor oligonucleotides. In contrast to the direct hybrid-
ization method, competitive DNA hybridization yields high
fluorescence in the absence of target DNA. When target DNA
is present, it binds the labeled competitor DNA, which, in turn,
is not available to hybridize to the microsphere, yielding low
fluorescence. Allele-specific primer extension (ASPE) or tar-
get-specific primer extension (TSPE), oligonucleotide ligation
assay (OLA), and single-base-chain extension (SBCE) are so-
lution-based chemistries coupled with subsequent microsphere
capture. By exploiting the natural properties of DNA poly-
merases and ligases, these chemistries incorporate a capture
sequence during the solution-based reaction (48). Both ASPE
or TSPE and OLA use a capture primer, which contains a
unique 5 sequence followed by a target-specific sequence. In
ASPE and/or TSPE, the primer can be extended by DNA
polymerase only if target DNA is present to supply the com-
plementary base for the 3 nucleotide. The label in ASPE
and/or TSPE is provided by a biotinylated deoxynucleotide
triphosphate. The OLA reaction is ligase dependent. In addi-
tion to the capture primer, a biotinylated probe homologous to
target DNA is present during an OLA. The capture primer and
reporter probes can be ligated only if target DNA is present in
the sample. Used for multiplex SNP detection, SBCE requires
independent reactions for each nucleotide query. For every
SNP being interrogated, one probe with a unique capture se-
quence is used to assay the possible alleles in separate wells
containing a different dideoxynucleoside triphosphate per well
(24). When the capture and target sequences are homologous,
a biotinylated dideoxynucleoside triphosphate is incorporated,
thereby terminating further extension.
The solution-based chemistries described above all take ad-
vantage of universal microspheres with nonspecific capture
FIG. 6. Illumina BeadArray. The SAM contains 96 1.4-mm fiber-optic bundles (bottom left). Each bundle is an individual array consisting of
50,000 5-m fiber-optic strands, each of which is chemically etched to create a microwell for a single bead (top left). The Sentrix BeadChips can
assay 1 to 16 samples at a time on a silicon slide (bottom right) that has been processed to provide microwells for individual beads (top right). Both
BeadArray platforms rely on 3-m silica beads that randomly self-assemble (center). (Adapted from reference 53 with permission of the publisher.
© 2009 BioTechniques.)
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sequences. The first universal sequences used to tag micro-
spheres were ZipCode/cZipCode capture sequences originally
used with SBCE in SNP genotyping assays (24, 84, 192, 219).
The 25-bp ZipCode sequences are based on random genomic
sequences from Mycobacterium tuberculosis (24). A unique
ZipCode sequence is included in the 5 end of the capture
probe used in the chemistries described above, while micro-
spheres are tagged with the complementary sequence (cZip-
Code). Additional sets of universal capture sequences have
been developed, including those by Tm Biosciences (xTAG;
Luminex Molecular Diagnostics, Inc., Toronto, Canada) and
EraGen (Madison, WI) (EraCode) (90). The sequences of the
xTAG (also Tag-It and FlexMAP) system consist of 3 of the 4
nucleotides, thereby decreasing the likelihood of nonspecific
hybridization to naturally occurring sequences. Since all of the
xTAG sequences are thermodynamically matched, variability
in hybridization efficiency is not an issue. The xTAG universal
bead technology is used for all commercial assays available
through Luminex. Based on the expanded genetic alphabet of
MultiCode technology, EraCode sequences incorporate syn-
thesized isoguanosine and 5-Me-isocytosine bases. EraCode
sequences are highly specific since the isoguanosine and 5-Me-
isocytosine bases will pair with each other but not naturally
occurring bases.
Although the feature density of suspension bead arrays is the
lowest of all the platforms reviewed, advantages abound that
make this platform the most practical for clinical microbiology
applications. The availability of universal bead sets and their
inherent flexibility make the development of user-defined ap-
plications feasible and relatively inexpensive. Although users
must carefully validate the positive fluorescent threshold for
each analyte in the multiplex, user-defined bead-based assays
provide experienced users a multitude of clinically relevant
applications (see below). Importantly, in 2008, Luminex ob-
tained FDA clearance for the first infectious-disease suspen-
sion bead array (xTAG RVP), which detects 12 respiratory
viruses and subtypes (106, 132). Although analyte-specific re-
agents (ASRs) also exist, the availability of FDA-cleared prod-
ucts is a critical step in getting this technology into less-expe-
rienced diagnostic microbiology laboratories. However, many
established clinical molecular microbiology laboratories rely
heavily on real-time PCR, which has minimal contamination
FIG. 7. Electronic microarray. (A) A positive electric current is applied to test sites, facilitating the active movement and concentration of
negatively charged DNA probes to the activated locations. (B) Once the first probe is bound to its targeted location(s) by streptavidin-biotin bonds,
the test site(s) can be deactivated, and current can be applied to a different test site. This process is repeated until all the probes are arrayed.
(C) Nanogen’s RVA ASR. Upon application of the probes to targeted test sites, extracted and amplified nucleic acids from a respiratory sample
passively hybridize to the microarray surface. If hybridization occurs, secondary probes that are specific for the target and that contain a nonspecific
detector sequence will bind. Secondary fluorescent detector oligonucleotides are used to measure positive hybridization reactions. Multiple probes
can be used per site when multiple fluorophores are incorporated. P1, parainfluenza virus type 1; P2, parainfluenza virus type 2; P3, parainfluenza
virus type 3; FB, influenza B virus; FA, influenza A virus; RSV, respiratory syncytial virus; BKGD, background. (Images courtesy of Nanogen.)
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risks. In contrast, the opening of postamplification tubes and
the subsequent pipetting steps in the workflow of suspension
arrays increase the risk for intra- and interrun contamination.
Careful consideration should be paid to contamination control
measures and the reestablishment of postamplification labora-
tory space in the era of real-time PCR. Nonetheless, the rela-
tive simplicity, powerful multiplexing capabilities, and afford-
ability of suspension bead arrays make this platform the most




Microarray technology has been used for over a decade to
investigate the differential gene expression of pathogens. Al-
though gene expression analyses have contributed significantly
to our understanding of pathogenic mechanisms, pathogen
responses to environmental stimuli, and host-pathogen inter-
actions, one could argue that the data from these investigations
have little direct impact on diagnostic microbiology. However,
as outlined below, microarray technology has been applied to
the detection and identification of various pathogens, patho-
gen discovery, antimicrobial resistance monitoring, and strain
typing. In addition, the monitoring of host responses to infec-
tion and therapy represents a burgeoning field that, when cou-
pled with pathogen-specific detection and monitoring, will be
the ultimate diagnostic platform for infectious diseases.
Microbial Detection and Identification
Perhaps the most promising area in applying microarray
technology in clinical microbiology is the use of low- or middle-
density microarrays for the simultaneous assessment of large
numbers of microbial genetic targets (64, 183). Specific micro-
bial gene amplification by either a broad-range or a multiplex
PCR prior to microarray analysis enhances test sensitivity. The
amplification of universal microorganism targets by broad-
range PCR followed by sequencing analysis has been consid-
ered a standard procedure (190); however, microarrays have
FIG. 8. Suspension bead array. (A) Microspheres 5.6 m in diameter are filled with different relative concentrations of an infrared dye and a red dye
to create 100 beads, each with a unique spectral identity. (B) Potential targets are amplified using a biotinylated primer and then denatured and hybridized
to microspheres tagged with target-specific sequence probes. Probe-target hybridization is measured using a streptavidin-bound green fluorophore.
(C) Flow cytometry is used to analyze the microsphere suspension. A red laser is used to determine the spectral identity of the bead and, therefore, the
probe being analyzed. The reporter fluorochrome is excited by a green laser, which quantifies the probe-target reaction on the microsphere surface.
(Panels A and C courtesy of Luminex Corporation; panel B adapted from reference 48 with permission from Elsevier [copyright Elsevier Inc. 2006].)
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emerged as potential tools for bacterial detection and identi-
fication given their high parallelism in screening for the pres-
ence of a wide diversity of genes. The most commonly used
gene targets have been the 16S bacterial and 28S fungal and
intergenic transcribed spacers (ITSs) in rRNA genes, and mi-
croarray technology has been incorporated to compensate for
the time-consuming sequencing identification procedure (190).
An oligonucleotide microarray targeting the 16S rRNA gene
was developed for the detection of a panel of 40 predominant
human intestinal bacterial pathogens in human fecal samples
(208). Assays using broad-range PCR incorporated with mi-
croarrays have been shown to allow rapid bacterial detection
and identification with positive blood cultures (5, 128). A sim-
ilar procedure was developed and used for the rapid diagnosis
of bloodstream infections caused by common bacterial patho-
gens in the pediatric and general populations (32, 173). PCR
amplification, in combination with an oligonucleotide microar-
ray, was used to identify Bacillus anthracis based on the rRNA
ITS region (144). Several studies reported the use of microar-
rays to identify pathogenic yeasts and molds by targeting the
ITS regions in fungal rRNA genes (80, 81, 110). Recently, a
DNA microarray was established to detect and identify 14
commonly encountered fungal pathogens in clinical specimens
collected from neutropenic patients (178).
The key for broad-range PCR amplification followed by
microarray identification to work is to target the right gene. It
is critical to use a gene “broad” enough so that most related
microorganisms can be covered in one amplification reaction.
On the other hand, the targeted gene should possess enough
polymorphic information to supply sufficient discriminatory
power to differentiate and characterize related microorgan-
isms. Degenerate primer sets can be designed to increase the
coverage of relatively variable genes. Other universal bacterial
genes have been used to detect and identify organisms using
microarrays. For mycobacterial detection and identification,
the gyrB, rpoB, and katG genes have been targeted by using
microarrays (61, 197). Microarrays targeting the 23S rRNA
and gyrB genes for bacterial detection and identification using
clinical specimens have been described (92, 102, 136). In ad-
dition to bacterial and mycobacterial organisms, microarrays
following broad-range PCR amplification have been used to
detect and identify fungal, parasitic, and viral pathogens (43,
101, 210).
Microarrays have also been incorporated with multiplex
PCR amplification for the simultaneous detection and identi-
fication of a panel of microbial pathogens in a single reaction.
Khodakov et al. described a novel microarray-based approach
for the simultaneous identification and quantification of hu-
man immunodeficiency virus type 1 (HIV-1) and hepatitis B
and C viruses in donor plasma specimens (96). A microarray
technique for the detection and identification of enteropatho-
genic bacteria at the species and subspecies levels was devel-
oped, covering pathogenic Escherichia coli, Vibrio cholerae,
Vibrio parahaemolyticus, Salmonella enterica, Campylobacter
jejuni, Shigella spp., Yersinia enterocolitica, and Listeria mono-
cytogenes (220). A microarray-based multiplexed assay was de-
veloped to detect foot-and-mouth disease virus with rule-out
assays for two other foreign animal diseases and four domestic
animal diseases that cause vesicular or ulcerative lesions that
are indistinguishable from those of foot-and-mouth disease
virus infection of cattle, sheep, and swine (111). Bøving et al.
reported the development of a novel multiplex PCR with prod-
uct detection by the Luminex suspension array system covering
a panel of bacterial and viral pathogens causing meningitis.
This system detected and identified nine microorganisms in-
cluding Neisseria meningitidis, Streptococcus pneumoniae, E.
coli, Staphylococcus aureus, L. monocytogenes, Streptococcus
agalactiae, herpes simplex virus types 1 and 2, and varicella
zoster virus directly from cerebrospinal fluid (15). The ResPlex
I system, manufactured by Qiagen (Valencia, CA), was used to
detect a panel of bacterial pathogens related to community-
acquired pneumonia from tracheal aspirates collected from
hospitalized antibiotic-treated children. The data indicated
that the ResPlex I system significantly enhanced the pathogen-
specific diagnosis of community-acquired pneumonia in chil-
dren (39). This gene-specific, multiplex amplification followed
by a microarray identification system provides a great example
for additional clinical diagnostic applications such as the de-
tection and differentiation of respiratory viral pathogens,
which is described in detail below.
Respiratory Viral Pathogen Detection in Connection with
Multiplex PCR Amplification
Respiratory infections caused by a panel of bacterial, viral,
and fungal pathogens usually present with similar signs and
symptoms that are nearly indistinguishable by clinical diagno-
sis. Simultaneous testing for all possible pathogens is an effi-
cient means to obtain a conclusive result. In addition, assaying
for all potential pathogens may yield information regarding
possible coinfections or induced secondary infections. The first
promising respiratory microarray system was described in
2002, which incorporated 1,600 unique 70-mer-long oligonu-
cleotide probes covering approximately 140 viral genome se-
quences (206, 207). This ViroChip system was used to identify
the severe acute respiratory syndrome virus as a coronavirus
(163), for the discovery of a human parainfluenza virus type 4
infection associated with respiratory failure (27) and human
coronavirus and rhinovirus in nonasthmatic patients (98), and
for the diagnosis of a human metapneumovirus causing critical
respiratory illness (26). A resequencing microarray based on
the Affymetrix GeneChip platform that used short oligonucle-
otides to simultaneously provide both species-level and strain-
level identification of respiratory pathogens was developed
(127, 209). The system was able to detect and identify 26
respiratory pathogens including the novel influenza virus sub-
types H5N1 and H1N1 (115, 116). Another comprehensive and
panmicrobial microarray, the GreeneChipResp system, was
developed and later used for the detection of respiratory vi-
ruses and the subtype identification of influenza A viruses (150,
157). In addition to the detection and identification of respi-
ratory pathogens, several formats of microarrays that detect
the whole coronavirus genus (42) and detect and type influenza
viruses (113, 131, 170, 227) have been described.
Several commercial products are available for the detection
of a panel of respiratory viruses, which incorporate microarrays
as the identification method (18, 106, 109, 112, 126, 132, 143,
148, 160, 185). These products include the Infiniti RVP from
AutoGenomics, Inc. (Carlsbad, CA); the MultiCode-PLx RVP
from EraGen Biosciences (Madison, WI); the ResPlex II assay
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from Qiagen (Valencia, CA); the Ngen respiratory virus ASR
assay from Nanogen (San Diego, CA); and the xTAG RVP
from Luminex Molecular Diagnostics (Toronto, Canada). Ta-
ble 2 contrasts these commercially available kits. Among them,
the EraGen, Qiagen, and Luminex molecular diagnostics sys-
tems incorporate multianalyte profiling by a liquid-bead mi-
croarray system developed by Luminex (discussed above) (48).
Specific applications of this technology for nucleic acid detec-
tion include SNP genotyping, genetic disease screening, gene
expression profiling, and microbial detection and typing. Al-
though suspension bead arrays are amenable to high-through-
put nucleic acid detection, the efficiency of the front-end mul-
tiplex PCR amplification limits the number of pathogens that
can be included in one reaction. With the implementation of
novel multiplex amplification procedures, numbers of targets
included in one reaction can be significantly increased without
a significant loss of sensitivity (112, 166).
Simultaneous Detection and Typing of
Human Papillomaviruses
Persistent infection with known high-risk human papilloma-
virus (HPV) types is a significant risk factor for cervical cancer
and is increasingly being recognized as playing a role in other
cancers. Recently, HPV vaccines have demonstrated effective-
ness in preventing type-specific persistent infection and dis-
ease. To monitor the impact of vaccine implementation strat-
egies, determine type-specific persistence, and evaluate the
clinical significance of coinfection with multiple genotypes,
HPV testing will require type-specific results. A high-through-
put, sensitive, specific, and reproducible HPV detection and
typing assay is therefore highly desirable. Most established
HPV typing assays are based on consensus PCR to amplify the
relatively conserved L1 gene region with hybridization, restric-
tion enzyme digestion, or sequencing of the amplicon to de-
termine type(s). Recently, several studies were aimed at eval-
uating the usefulness of microarray technology for the
simultaneous detection and typing of HPV in routine clinical
specimens. A user-developed HPV DNA microarray for high-
risk HPV genotyping was evaluated by using a panel of malig-
nant and nonmalignant cervical smears. This approach pro-
vides the potential to improve the clinical management of
patients with cervical cytological abnormalities (3). Several
systems that combine multiplex PCR amplification and mi-
croarray identification have been reported to provide rapid
and reliable diagnostic tools for HPV detection and typing that
are amenable to automation (73, 119, 140, 145). Additional
studies that incorporated microarrays to detect and character-
ize high-risk mucosal HPV types (66), betapapillomavirus
types (65), and the frequencies of 23 HPV types in women with
and without cytological anomalies (193) have been reported. A
TABLE 2. Comparison of commercially available, microarray-based kits for detection and identification of respiratory virusesa
































































































a Abbreviations: Tem, target-enriched multiplex; Flu, influenza virus; PIV, parainfluenza virus; RSV, respiratory syncytial virus; hMPV, human metapneumovirus;
RhV, rhinoviruses; EnV, enteroviruses; CoV, coronavirus; RT, reverse transcription.
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novel DNA detection assay incorporating the Luminex suspen-
sion array was reported and was applied to the genotyping of
HPV in cervical samples (141). The molecular inversion probe
microarray assay, originally applied to large-scale human SNP
detection, has been used for HPV detection and typing to
demonstrate the potential of the method for the detection and
characterization of any microbe (1).
Rapid Detection and Characterization of Methicillin-
Resistant Staphylococcus aureus
Staphylococcus aureus, including methicillin-resistant S. au-
reus (MRSA), is an important pathogen in hospitals and, in-
creasingly, in communities around the world. Advanced labo-
ratory techniques, including diagnostic microarray analysis,
have been sought to rapidly identify staphylococcal isolates and
determine antimicrobial susceptibility patterns. DNA microar-
ray analyses of large samples of clinically characterized com-
munity-acquired MRSA strains have been reported, which
provide broad insights into evolution, pathogenesis, and dis-
ease emergence (57, 99, 168). DNA microarrays based on the
Array-Tube platform (ClonDiag Chip Technologies, Jena,
Germany) have been used for characterizing and genotyping
staphylococcal DNA, including their relevant resistance deter-
minants and virulence factors (137–139). Microarrays provide
a valuable epidemiological tool for the detailed characteriza-
tion of MRSA isolates and comparison of strains at a global
level (137). In addition, several techniques incorporating pep-
tide and/or nucleic acid probes and conventional and real-time
PCR have been used to take advantage of the rapid enrich-
ment of automated blood culture instruments to rapidly iden-
tify MRSA from flagged blood cultures when gram-positive
cocci in clusters are observed. The combination of novel mul-
tiplex PCR amplification and suspension bead array detection
(StaphPlex) for the rapid detection and characterization of
staphylococci directly from positive blood culture bottles was
described (191). The StaphPlex system provides simultaneous
staphylococcal identification, antibiotic resistance determinant
detection, detection of Panton-Valentine leukocidin, and de-
termination of staphylococcal cassette chromosome mec types
I to IV within 5 h. This approach potentially impacts antibiotic
usage when gram-positive cocci in clusters are detected by
reducing the unnecessary use of vancomycin, which is often
used empirically to treat patients until susceptibility results are
available (191). A similar system (MVPlex) was developed and
was used to screen for MRSA in nasal swabs (154). Notably,
the MVPlex system detects 13 different molecular targets in-
cluding vancomycin-resistant Enterococcus.
Determination of Antimicrobial Drug Resistance
Another successful application of microarray techniques in
clinical microbiology is the determination of antimicrobial re-
sistance by simultaneously detecting a panel of drug resistance-
related mutations in microbial genomes (21, 36, 72, 153, 196,
224, 225). The emergence of multidrug-resistant tuberculosis
and extensively drug-resistant tuberculosis and time-consum-
ing phenotypic antimycobacterial susceptibility procedures
have stimulated the pursuit of microarray platforms in antitu-
berculosis drug resistance determinations. High-density DNA
oligonucleotide arrays have been used for parallel species iden-
tification and rifampin resistance-related mutations in myco-
bacteria (197) and, more specifically, for the detection of M.
tuberculosis strains that are resistant to rifampin (40, 176, 222)
or isoniazid, kanamycin, streptomycin, pyrazinamide, and
ethambutol (41, 189, 204). Oligonucleotide microarrays were
developed to analyze and identify drug-resistant M. tuberculo-
sis strains, and it was found that the results were comparable
with those of standard antimicrobial susceptibility testing (69,
134, 184). A low-cost and -density DNA microarray was de-
signed to detect mutations that confer isoniazid and rifampin
resistance in M. tuberculosis isolates. The low-cost and -density
array protocol takes 45 min after PCR amplification, with only
minimal laboratory equipment required (7). Antonova and
colleagues developed a method for the detection and identifi-
cation of mutations in the M. tuberculosis genome determining
resistance to fluoroquinolones by hybridization on biological
microchips (6). A recently developed QIAplex system com-
bines a novel multiplex PCR amplification and suspension
bead array identification for the simultaneous detection of 24
M. tuberculosis gene mutations responsible for resistance to
isoniazid, rifampin, streptomycin, and ethambutol (63). Sev-
eral studies that detected antibiotic resistance-related muta-
tions in bacterial genomes have been reported (2, 68, 153, 202,
221, 225).
Microarray-based techniques face several application chal-
lenges to determine antimicrobial resistance in the clinical
setting. First, genomes of some pathogens continue to mutate
under natural and therapeutic selective pressures, which is well
demonstrated by HIV-1. An Affymetrix microarray was devel-
oped to provide HIV-1 antiretroviral-drug-resistant profiles
(104, 198, 213). The product was discontinued due to rapidly
emerging HIV-1 genome mutations. The company now has a
comprehensive, high-density microarray available to identify
every mutation in resistance-related HIV-1 genomes. Second,
molecular mechanisms for many antimicrobial drug resistances
remain to be discovered while novel resistance genes and mu-
tations continue to emerge. It takes considerable time and
effort to decipher all of the resistance-related mutations and
transfer the basic science findings to clinical applications. For
M. tuberculosis, until such knowledge is available, the currently
used phenotypic methods for identifying resistance will con-
tinue to play an invaluable role in optimizing the therapy of
persons with tuberculosis.
Microbial Typing
Numerous studies that use microarrays for microorganism
typing by taking advantage of its simultaneous detection of a
variety of genomes have been reported. The accurate identifi-
cation and prompt typing of pathogens causing diarrheal dis-
eases are critical for directing clinical intervention, including
appropriate antibiotic administration, and facilitating epidemi-
ological investigations. Microarray-based approaches along
with other genetic approaches that can be used to support or
replace the classical serotyping method for several conven-
tional diarrhea bacterial pathogens have already been offered.
The use of microarrays has included Salmonella, Helicobacter,
and Campylobacter species (46, 56, 155, 164, 201, 212). PCR
followed by a microarray hybridization step has been used for
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the detection and typing of E. coli virulence genes (28, 199). A
serotype-specific DNA microarray for the identification of clin-
ically encountered Shigella and pathogenic E. coli strains was
recently described (114). Diagnostic microarrays based on the
ArrayTube format were devised for virulence determinant de-
tection as well as for protein-based serotyping of E. coli (4,
100). A novel ArrayTube assay, which incorporates oligonu-
cleotide DNA probes representing 24 of the most epidemio-
logically relevant O antigens and 47 H antigens, has been
described for fast DNA serotyping of E. coli (9). Microarrays
have also been used to characterize and type other gastroen-
teritis-causing viral pathogens including rotavirus, norovirus,
and astrovirus (29, 77, 86, 103, 123). Beyond diarrheal illnesses,
Pas et al. reported the comparison of reverse hybridization,
microarray, and sequence analysis for hepatitis B virus (HBV)
genotyping, suggesting that the InnoLipa HBV genotyping
strip assay, a microarray-based system, detected dual infections
and was an easy and quick tool for HBV genotyping (152).
Microbial Gene Expression Profiling
The quantification of multiple microorganisms simulta-
neously using microarray techniques has rarely been reported,
probably due to technical difficulties. Instead, the detection
and monitoring of the gene expressions of individual microor-
ganism genomes during infection have begun to generate
meaningful data (16, 62). Whole-genome microarrays for M.
tuberculosis were first described using the amplicon arrays de-
veloped at Stanford to define gene expression responses to
isoniazid and ethambutol (214). Subsequently, microarrays
have been used to monitor M. tuberculosis gene expression
responses to a variety of environmental conditions and expo-
sure to antibiotics (11, 93, 161, 180, 203). M. tuberculosis gene
expression patterns associated with resistance and susceptibil-
ity and mycobacterial survival during infection have been in-
vestigated by use of oligonucleotide microarrays (60, 94, 165).
The transcriptional profile of M. tuberculosis from human lung
samples has been studied; during pulmonary tuberculosis, M.
tuberculosis actively transcribes a number of genes involved in
active fortification and evasion from host defense systems
(158). Microbial candidate genes have been studied by differ-
ential-expression microarrays for discrimination between in-
fection and disease caused by M. tuberculosis (87).
Gene expression profiles of other bacterial and fungal infec-
tions have also been studied by microarrays (17, 37, 44, 45, 67,
85, 121, 124, 162, 181, 218). A concordance of the gene ex-
pression data between intracellular Shigella and Salmonella has
been noted, although they colonize different niches inside the
cell (124). So far, most studies of microbial gene expression
profiling have been limited in research. Techniques used in
these studies need to be validated to ensure that sufficient
amounts of mRNA are extracted such that gene expression
data are not compromised. The host-pathogen interactions
that define a disease are clearly complex, and other genotypic
and phenotypic data need to be integrated to clarify the intri-
cate cross talk from host to pathogen and the environmental
cues that lead to the expression of bacterial virulence factors in
vivo. Nevertheless, microbial gene expression profiles reveal a
complete picture of the metabolic state of bacteria under a
particular condition, thereby providing a potential tool for the
diagnosis and monitoring of microbial infection and disease.
Host Gene Expression Profiling during Microbial Infections
Pathogen-induced phenotypic changes in a host are often
accompanied by marked changes in host gene expression. Ge-
nome-wide expression profiling of the hosts, in addition to the
pathogens, has become increasingly important for studying
host-pathogen interactions (88). The advent of microarray
technology has greatly expanded our ability to monitor changes
in host gene expression. The cellular transcriptional response
to human cytomegalovirus was globally monitored with an
oligonucleotide array in 1998 (223). Subsequently, oligonucle-
otide microarrays have been generated to measure host gene
expression profiles in response to E. coli, Candida albicans, L.
monocytogenes, influenza virus, and respiratory syncytial virus
infections (34, 58, 82). A microarray was generated to incor-
porate a series of host response genes including those involved
in inflammation and chemotaxis as well as those involved in the
synthesis of prostaglandins, Toll-like receptors, and T-cell reg-
ulation (97). Such a microarray system has been used to de-
termine immune responses in normal human monocytes after
fungal pathogen infections and antifungal drug inoculation
(35, 97, 174). Microarrays have been implemented to generate
gene expression profiles for viral hepatitis infections, which
provide enormous diagnostic and therapeutic potential (75, 76,
147, 171, 211).
Several studies that used microarray-based techniques to
detect and characterize host gene expression profiles for sepsis
have been reported. Microarray technology was first used to
analyze tissue-specific changes in gene expression induced by
sepsis in animal models (33). Subsequently, numerous studies
that used host gene expression profiling toward sepsis diagnos-
tics, pathogen type differentiation, and clinical outcome pre-
diction have been described (Table 3) (55). The rapid deter-
mination of a host sepsis transcriptome provides an early
differential diagnosis and clinical outcome prediction. Current
microarray-based techniques using host gene expression pro-
files are limited due to the background variation among and
within the individuals studied and poor quality control built
into the microarrays. Therefore, the gene expression differ-
ences notified by the microarrays have to be verified by gene-
specific quantitative real-time PCR assays (95).
Host Genomic Polymorphism Determination
When infections, especially chronic infections, are viewed as
horizontally acquired genetic diseases, it makes sense to view the
pathogen and host as an integrated system. Host genetic poly-
morphisms that influence the host immune response to infectious
agents, thereby determining susceptibility to certain diseases and
pathological conditions, which has been well explored in sepsis,
have been described (118). SNP analysis is a powerful tool for the
mapping and diagnosing disease-related alleles. While sequenc-
ing remains the “gold standard” to determine host genetic vari-
abilities, microarray-based techniques may become a simple,
rapid, automatic, and user-friendly format for screening and de-
tecting a large panel of related SNPs simultaneously. An Af-
fymetrix HuSNP assay was used to study the role of human
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genomic SNPs in the pathogenesis of human parvovirus B19
infection, and relevant SNPs revealed by the microarray study
were further confirmed by allele-specific real-time PCR assays
(95). A microarray was developed for the simultaneous genotyp-
ing of four host SNPs associated with the therapeutic effect of
interferon in hepatitis C virus patients (186). These preliminary
data suggest that a genetic predisposition is associated with the
pathogenesis and development of microbial infections.
CONCLUDING REMARKS
Microarrays have the unprecedented potential to simulta-
neously detect and identify thousands of microbial genes,
which provides another evolutionary technical advance in the
field of clinical microbiology. Although, historically, microar-
rays have been used largely for gene expression studies, mi-
croarrays have gradually been applied in the detection and
TABLE 3. Selected sepsis studies using microarray-based host gene expression




Mouse Microarray technology provides a powerful new tool for
rapidly analyzing tissue-specific changes in gene
expression induced by sepsis
33
Hu95aVer2 GeneChip,
Affymetrix (Santa Clara, CA)
Adult patients The host inflammatory responses to gram-negative and
gram-positive stimuli share some common response
elements but also exhibit distinct patterns of cytokine





Mouse Both gram-positive sepsis and gram-negative sepsis share a
final common pathway involved in the pathogenesis of
sepsis, but certain genes are differentially expressed
under distinct regulation
221
Arraytor human 500-1 cDNA,
SIRS-Laboratory (Jena,
Germany)
Adult patients Microarrays can identify typical gene expression profiles for
blood samples from patients with severe sepsis
156
Hu 133A and 133B GeneChip,
Affymetrix
Healthy adult blood leukocytes
receiving bacterial endotoxin
stimulus
Human blood leukocyte response to acute systemic
inflammation includes the transient dysregulation of
leukocyte bioenergetics and modulation of translational
machinery; these findings provide insight into the
regulation of global leukocyte activities as they relate to
innate immune system tolerance and increased









Adult patients Blood transcriptional profiling is a valuable approach not
only for patient stratification but also to identity new
genes possibly involved in sepsis pathophysiology
149
Mouse 430 2.0 GeneChip,
Affymetrix
Mouse T-cell receptor signaling and mitogen-activated protein
kinase signaling were significantly altered by sepsis
129
U74Av2 GeneChip, Affymetrix Mouse Sepsis induces common inflammatory response gene
changes in mouse leukocyte gene expression that can be
used to diagnose sepsis
31
Adelaide Microarray,
Compugen, San Jose, CA)
Adult patients The signature genes reflect suppression of neutrophils’
immune and inflammatory function by sepsis; gene
expression profiling therefore provides a novel approach
to advance our understanding of the host response to
sepsis
188
430A GeneChip, Affymetrix Mouse Sepsis induces alterations in balance of pro- and
antiapoptotic transcriptional networks, and bcl-2
overexpression improves survival in sepsis
205
U133 Plus 2.0 GeneChip,
Affymetrix
Pediatric patients Genome-level alterations of zinc homeostasis may be
prevalent in clinical pediatric septic shock
216
U133 Plus 2.0 GeneChip,
Affymetrix
Adult patients Sepsis has a unique gene expression profile that is different
from that for uninfected inflammation and becomes
apparent prior to expression of the clinical sepsis
phenotype
89
U133 Plus 2.0 GeneChip,
Affymetrix
Adult patients Toll-like receptors and downstream signaling genes are
differentially expressed in critically ill patients developing
sepsis compared with those with sterile inflammation;
these expression differences occur before phenotype-
based diagnosis of clinical sepsis
120
U133 Plus 2.0 GeneChip,
Affymetrix
Adult patients There was evidence of sepsis-related immunosuppression
and reduced inflammatory response in mononuclear cells
on a transcriptome level; these characteristic
transcriptional changes can be used to aid the diagnosis
of sepsis
187
a Distributed by ResGen Invitrogen (Huntsville, AL).
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characterization of microbial pathogens, determination of an-
timicrobial resistance, typing of microbial pathogens, and mon-
itoring of microbial infections by investigating host genomic
expression and polymorphism profiles. Even with these major
advances, the potential power behind microarray applications
in clinical microbiology has yet to be fully realized. The ability
to detect multiple pathogens and/or monitor the variability of
normal microbial populations in a disease process could trans-
form our current understanding of infectious diseases. In ad-
dition, massively parallel sequencing performed by microarray
analysis offers the opportunity of sequencing directly from
complex clinical specimens. This metagenomics approach will
allow a comprehensive analysis of every nucleic acid in the
specimen. For these robust applications, high-density microar-
ray platforms must be able to transition from translational
research laboratories to the clinical laboratory. It is unlikely
that traditional, planar microarrays will soon appear in clinical
microbiology laboratories due to their high cost, relative lack
of flexibility, and limited throughput. The ideal microarray
platform for the diagnostic laboratory is a low- to medium-
density array that offers limited, reliable, and straightforward
results without the need for sophisticated equipment and data
management (133). Indeed, platforms that have begun to meet
these criteria have been developed, such as electronic microar-
rays and suspension bead arrays.
With the potential power of microarray analysis comes
abundant challenges, particularly in relation to the diagnostic
laboratory. Several critical issues need to be resolved before
microarray-based techniques can be widely implemented in
clinical microbiology services. Due to the potential variability
in multiple steps included in the microarray analysis, it is dif-
ficult to compare quantitative data between, and even within,
microarray experiments. Substantial obstacles still exist along
the entire spectrum of preanalytical-to-postanalytical analysis.
Heterogeneous clinical specimens present unique challenges
with respect to sensitivity, specificity, quantification, and data
analysis of microarrays that are not encountered during the
analysis of pure cultures. In addition, optimization of extrac-
tion, labeling, and hybridization; incorporation of appropriate
quality controls, design, and implementation of clinical valida-
tion studies; and management and interpretation of data re-
main challenges in a clinical setting. Moreover, laboratories
must account for microarray reproducibility in production and
analysis, cost of implementation, acquisition of appropriately
skilled laboratorians, as well as intellectual property and reim-
bursement issues. Compared to real-time PCR, microarray
analysis requires additional manipulations including hybridiza-
tion and washing, which increase the contamination risk and
the amount of hands-on time needed, both steps backwards in
diagnostic molecular microbiology.
Although improvements are still needed to make the major-
ity of microarray applications amenable to clinical microbiol-
ogy laboratories, the future role of these robust technologies in
diagnostic microbiology is indisputable. Microarray-based
analyses will revolutionize infectious disease diagnostics
through the detection and identification of previously unknown
or unsuspected pathogens, by transforming our current view of
multiplexed laboratory testing, and by expanding pathogen de-
tection to include bacterial population-based analyses and
host-specific responses (135). As more pathogen genomes and
targeted genes are sequenced, costs associated with microarray
production decrease, and FDA-cleared products become avail-
able, diagnostic applications of microarray-based analyses will
continue to expand. As PCR has done in the last 25 years, and
more recently real-time PCR, microarray technology will un-
doubtedly transform the diagnostic capabilities of clinical lab-
oratories, ushering us into a new molecular revolution.
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